Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)
China flag China · Delayed Price · Currency is CNY
8.08
-0.13 (-1.58%)
Aug 14, 2026, 3:00 PM CST

SHA:603707 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
585.83581.54826.14-189.451,0911,059
Depreciation & Amortization
242.98242.98174.85154.06139.5393.22
Other Amortization
0.130.130.190.190.190.2
Loss (Gain) From Sale of Assets
3.263.260.040.040.111.03
Asset Writedown & Restructuring Costs
008.640.0310.227.23
Loss (Gain) From Sale of Investments
-32.61-32.61-7.8185.58-24.1-24.57
Provision & Write-off of Bad Debts
6.736.738.22-3.05-0.423.22
Other Operating Activities
213.87-127.68-34.841,241-99.4387.47
Change in Accounts Receivable
-321.33-321.33-13.19163.36-1,456-148.2
Change in Inventory
591.79591.79598.72213.28-731.57-444.05
Change in Accounts Payable
191.05191.05-185.77224.661,71046.82
Change in Other Net Operating Assets
-31.84-31.84-20.08-21.25-15.113.45
Operating Cash Flow
1,5291,1831,5011,619595.45683.63
Operating Cash Flow Growth
4.38%-21.21%-7.28%171.92%-12.90%-

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-389.38-560.15-506.82-419.07-470.08-440.76
Sale of Property, Plant & Equipment
0.040.0400.150.110.54
Cash Acquisitions
0.72-----13.87
Investment in Securities
-557.16-226.41-459.05-757.4736.06610.72
Other Investing Activities
22.1528.1255.1414.3433.4213.51
Investing Cash Flow
-923.63-758.41-910.73-1,162-400.5170.14

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-2,1791,8663,3993,3582,126
Total Debt Issued
3,0012,1791,8663,3993,3582,126
Long-Term Debt Repaid
--1,989-2,373-3,094-3,441-2,687
Total Debt Repaid
-1,726-1,989-2,373-3,094-3,441-2,687
Net Debt Issued (Repaid)
1,275189.34-506.04305.39-83.41-560.94
Issuance of Common Stock
----0.3741.17
Repurchase of Common Stock
-15.55-15.01-12.04-5.72-1.13-0.87
Common Dividends Paid
-214.85-218.42-213.19-248.47-226.65-191.75
Other Financing Activities
-10.6-10.6----200
Financing Cash Flow
1,034-54.69-731.2851.2-310.81-912.39

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-32.48-10.59-16.783.18-16.1120.05
Net Cash Flow
1,607359.11-157.49591.51-131.97-38.57

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
1,139622.64994.411,200125.37242.87
Free Cash Flow Growth
42.64%-37.39%-17.14%857.27%-48.38%-
Free Cash Flow Margin
28.24%15.60%25.34%30.53%3.38%6.59%
Free Cash Flow Per Share
0.700.390.600.760.080.15
Levered Free Cash Flow
752.93370.19431.641,279-540.91-186.72
Unlevered Free Cash Flow
789.25404.72478.931,330-504.75-129.08

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
68.992104.54108.8691.0146.06
Change in Working Capital
508.43508.43525.78330.47-521.49-543.45